Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance

Motoi Fukumoto, Tatsuya Amanuma, Yoshikazu Kuwahara, Tsutomu Shimura, Masatoshi Suzuki, Shiro Mori, Hiroyuki Kumamoto, Yohei Saito, Yasuhito Ohkubo, Zhenfeng Duan, Kenji Sano, Tomohiro Oguchi, Kazuyuki Kainuma, Shinichi Usami, Kengo Kinoshita, Inchl Lea and Manabu Fukumoto

1Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai; 2Department of Oral and Maxillofacial Surgery, Tohoku University, Sendai; 3Division of Oral Pathology, Department of Oral Medicine and Surgery, Graduate School of Dentistry, Tohoku University, Sendai; 4Department of Radiopharmacy, Tohoku Pharmaceutical University, Sendai, Japan; 5Department of Pathology, School of Medicine, Shingiku University, Matsumoto; 6Department of Otorhinolaryngology, School of Medicine, Shindu University, Matsumoto, Japan; 7Graduate School of Information Sciences, Tohoku University, Sendai; 8Department of Pathology, Asan Medical Center, Seoul, Korea

Key words
GTP-binding proteins, head and neck neoplasms, neoplasms, radiation, radiation oncology

Correspondence
Manabu Fukumoto, Department of Pathology, IDAC, Tohoku University, 4-1 Seiryou-machi, Aoba-ku, Sendai, Japan.
Tel: +81-22-717-8507; Fax: +81-22-717-8512; E-mail: fukumoto@idac.tohoku.ac.jp

Funding Information
Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Japan Science and Technology Agency.

Received January 29, 2014; Revised July 18, 2014; Accepted July 22, 2014

Cancer Sci 105 (2014) 1351–1359
doi: 10.1111/cas.12489

Radiotherapy is one of the major therapeutic modalities for eradicating malignant tumors. The existence of radioresistant cells remains one of the major obstacles in radiotherapy and chemoradiotherapy. Ordinary radiotherapy for cancers is composed of fractionated radiation (FR), with approximately 2 Gy of X-ray irradiation once a day, 5 days a week, over a 5–8-week period. In order to develop more effective tumor radiotherapies, we established three human and one murine clinically relevant radioresistant (CRR) cell lines independently. These cells continue to proliferate under exposure to 2 Gy/day for more than 30 days in vitro. The total dose to these CRR cells over the whole process added up to more than 1500 Gy. We carried out cDNA microarray analyses of differential gene expression in association with the CRR phenotype. We found that the Guanine nucleotide-binding protein 1 (GBP1) gene was overexpressed in all of the CRR cells examined.

GBP1 is a member of the large GTPase family. The human large GTPase family consists of seven members, encoded by a gene cluster located on chromosome 1. GBP1 is one of the genes most strongly induced by interferons. GBP1 is highly expressed in endothelial cells, where it inhibits the proliferation and invasion of endothelial cells in response to γ-interferon and is activated by inflammatory cytokines in vitro and in vivo. Downregulation of GBP1 by siRNA resulted in higher levels of hepatitis C virus replication in a human hepatoma cell line, HuH-7. In addition to the GTPase activity and its involvement in viral infections, GBP1 overexpression also contributes to cell survival by inhibiting apoptosis in human umbilical vein endothelial cells after growth factor and serum depletion.

Ovarian cancer cases with GBP1 protein overexpression are resistant to paclitaxel, leading to poor prognoses. GBP1 overexpression is directly associated with moderate levels of paclitaxel resistance in ovarian cancer cell lines. Higher GBP1 levels are associated with higher pathological stages, positive perineural invasion, and poorer prognosis of patients with oral squamous cell carcinoma. In this study we found that GBP1 is necessary but not sufficient for cellular radioresistance...
sistance in vitro. We carried out immunohistochemical studies on clinico-pathological specimens from head and neck cancers (HNC) to confirm the relevance of GBP1 in cancer treatment. This study revealed that GBP1 is one of the key molecules contributing to radioresistance.

Materials and Methods

Cell culture and drugs. Human cancer cell lines SAS, HepG2, and KB and a mouse breast cancer cell line, MM102, were obtained from the Cell Resource Center for Biomedical Research (IDBC, Tohoku University, Sendai, Japan). We established CRR cells lines SAS-R1, HepG2-8960-R, and KB-R by exposing these parental cells to FR of X-rays for more than 5 years. For the maintenance of the CRR phenotype, FR at 2 Gy was carried out every 24 h. All cells used in this study were maintained in RPMI-1640 medium (Nacalai Tesque, Kyoto, Japan) and supplemented with 5% FBS (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere at 37 °C in air with 5% CO2. Acute exposure experiments were carried out with cells in the exponential growth phase, 24 h after the last maintenance irradiation. We introduced pIRES GBP1 expression vectors into CRR cells by Lipofectamine 2000 (Invitrogen) and selected colonies resistant to 100 µg/mL G418 (Geneticin, Grand Island, NY, USA).

Irradiation. X-ray irradiation was carried out in a 150-KVp X-ray generator (MBR-1520R; Hitachi, Tokyo, Japan) with a total filtration of 0.5 mm aluminum plus 0.1 mm copper filter, at a dose rate of 1.0 Gy/min.

Cell survival assay after irradiation. Cell survival was determined by the modified high density survival (MHDS) assay. (15)

Microarray analysis. Genome-wide expression arrays (Illumina, San Diego, CA, USA) were used for the analysis of SAS (human HG6, version 3, 48 803 genes) and HepG2 (human HG6, version 1, 47 296 genes). Data were analyzed by TransGenic (Kumamoto, Japan). For MM102, a 3D- Gene mouse Oligo chip 24k (23 522 genes; Toray Industries, Tokyo, Japan) was used and the data were analyzed by Toray Industries using GeneSpring GX10 (Agilent Technologies, Santa Clara, CA, USA). HepG2 versus HepG2 cancer stem cell (CSC) analysis was carried out by MOGERA-Array self (Tohoku Chemical, Iwate, Japan).

Antibodies. The primary antibodies used were as follows: anti-β-actin (A5316; Sigma, St. Louis, MO, USA), anti-GBP1 (15303-1-AP; Proteintech Group, Chicago, IL, USA), purified anti-H2AX-phosphorylated (γH2AX) (Ser139; BioLegend, San Diego, CA, USA), anti-Oct4 antibody 7E7 (ab105931; Abcam, Cambridge, MA, USA), CD34 (ab8158, Abcam), anti-GBP2 N1C1 (GTX114426; GeneTex, Irvine, CA, USA), anti-GBP3 C-term (AP18451b; Abgent, San Diego, CA, USA), anti-GBP5 N1N3 (GTX106994; GeneTex), anti-TAPI 53H8 (GTX10356; GeneTex), and interleukin (IL)-15 (sc-1296; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The secondary antibodies used were as follows: goat anti-rabbit IgG (H1202; Nichirei Bioscience, Tokyo, Japan), mouse anti-rat IgG (H1104; Nichirei Bioscience), Alexa Fluor 488 goat anti-mouse IgG (A11001; Invitrogen), and Alexa Fluor 594 goat anti-rabbit IgG (A11012, Invitrogen).

Western blot analysis. Western blot of whole cell lysates was carried out as previously described. (16)

Reverse transcription-PCR. Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was synthesized by RT using SuperScriptII Reverse Transcriptase (Invitrogen). Reverse transcription-PCR of GBP1 was carried out using the primer pair 5′-CTGCACAGGCTCAGAAAA-3′ and 5′-AAGGCTCTGTCTTTAGCTT-3′. (13) Reverse transcription-PCR of ISG20 was carried out using the primer set 5′-ATCTCTGAGGTCCACCAAG-3′ and 5′-TTCAGTCTGACACAGCAGG-3′. (17) The RT-PCR was carried out using TB SYBR gPCR Mix (Toyobo, Osaka, Japan). The PCR conditions were: 95 °C for 1 min, followed by 40 cycles of 95 °C for 15 s, and 60 °C for 30 s using the Thermal Cycler Dice Real Time System (Takara, Shiga, Japan).

Immunofluorescence staining of culture cells. Immunofluorescence staining was carried out as previously described. (18) Images were randomly captured in a fluorescence microscope (BZ-8000; Keyence, Osaka, Japan). We scored γH2AX foci and Oct4-positive cells by counting 50 cells in total.

Animal experiments. This study was approved by Regulations for Animal Experiments and Related Activities, Tohoku University, and carried out as previously described. (16) Atelo Gene (Koken, Tokyo, Japan) was used to deliver siRNA into animal tissues according to the manufacturer’s protocol.

Immunohistochemistry. Tumor tissues were fixed in 10% formalin and immunohistochemical staining was carried out as described previously. (19)

In situ hybridization. GBP1 (NM_002053) gene expression in tumor tissues was visualized using RNAscope and the HybEZ system according to the manufacturer’s protocol (Advanced Cell Diagnostics, Hayward, CA, USA).

Demographic analysis. This study was approved by the committee of medical ethics, Shinshu University School of Medicine (No.354; Matsumoto, Japan) and Tohoku University, Graduate School of Medicine (No. 2011-42, 2013-1-1). We carried out immunohistochemical studies on biopsy specimens from HNC before treatment at Shinshu University Hospital and Tohoku University Hospital. The correlation between relative protein expression and clinicopathological data was analyzed using the Behrens–Fisher test.

Statistical analysis. Experiments in vitro were carried out in triplicate and were statistically analyzed using Student’s t-test.

Results

Identification of GBP1 overexpression by cDNA array analysis. We carried out a cDNA array analysis to identify genes whose expression was changed 12 h after exposure to 2-Gy X-rays (2-Gy-12 h). We compared the expression profile of CRR cells and their corresponding parental cells. In order to avoid the influence of the maintenance irradiation other than radioresistance, we also analyzed SAS-R1-NOIR cells, which were cultured CRR cells without maintenance exposure. We confirmed that NOIR cells were also radioresistant, as determined by the MHDS assay (Fig. S1a). We first compared SAS, SAS 2-Gy-12 h, SAS-R1 2-Gy-12 h, and SAS-R1 NOIR (Fig. 1a). We found 1636 genes whose expression in CRR cells was more than twice that in corresponding parental cells, regardless of irradiation. We also carried out the same analysis among the MM102 series and found 206 genes that were overexpressed in CRR cells compared with parental cells, regard-
less of irradiation. Compared with the corresponding parental cells, 23 genes were commonly overexpressed in SAS-R1 and MM102-R cells. We finally confirmed that two genes, GBP1 and ISG20, were commonly overexpressed in CRR cells of the HepG2 series (Fig. 1a,b).

Verification of GBP1 overexpression by RT-PCR. Compared with their corresponding parental cells, GBP1 expression was commonly higher (Fig. 1c) in HepG2-8960-R as well as SAS-R1 cells, whereas ISG20 expression was not.

Verification of GBP1 protein overexpression by Western blotting. All of the CRR cells examined showed higher GBP1 expression than their corresponding parental cells and NOIR cells (Fig. 1d). HepG2 and KB showed only a trace amount of the GBP1 protein, irrespective of irradiation. GBP1 protein expression was higher in NOIR cells than in parental cells. GBP1 expression in SAS-R1 NOIR and KB NOIR tended to be higher after 2-Gy irradiation than without irradiation. SAS, the most radioresistant line, showed the highest expression of GBP1 protein among the parental cells. These results confirmed that GBP1 protein expression was correlated to radioresistance. We picked up proteins directly connected with GBP1 on the network such as GBP2, GBP3, GBP5, TAP1 and IL-15 in reference to COXPRESdb (http://coxpresdb.jp/). No associations were observed among their protein levels (Fig. S2d).

Decreased radioresistance by GBP1 gene knockdown. In order to determine whether GBP1 was involved in radioresistance or not, the MHDS assay was carried out after cells were transfected with two types of GBP1 siRNA, GBP1_8 and GBP1_9 (Fig. S2a). During this period of experiments, GBP1 gene expression was suppressed (Fig. S2b). In all of the CRR cells examined, GBP1 knockdown cancelled radioresistance to the levels of their parental cells (Figs 2 and S1b). Furthermore, GBP1 knockdown increased radiosensitivity in parental cells. These indicate that GBP1 is one of the key molecules commonly involved in coping with radiation exposure, both in CRR and parental cells. Because suppression with GBP1_8

Fig. 1. Overexpression of guanine nucleotide-binding protein 1 (GBP1) in clinically relevant radioresistant (CRR) SAS, HepG2, KB, and MM102 cells. (a,b) Compared to corresponding parental cells, overexpression of GBP1 and ISG20 was found in all CRR cells. SAS cells had two different GBP1 target probes. (c) GBP1 but not ISG20 overexpression was reconfirmed in CRR cells by RT-PCR. In all the combinations of cell lines, CRR cells 12 h after 2-Gy irradiation (CRR+) showed higher GBP1 gene expression than parental cells without irradiation (P) and parental cells 12 h after 2-Gy irradiation (P+). (d) GBP1 protein expression in CRR cells and CRR-NOIR cells 12 h after 2-Gy irradiation or without irradiation were higher than their parental cells. NOIR cells were without irradiation for over 30 days, in order to avoid the influence of maintenance radiation. RNA from three independent exposure treatments was combined for the cDNA microarray and RT-PCR analysis. cDNA microarray analysis of the SAS group was carried out in duplicate.

Fig. 2. Radiosensitivity after guanine nucleotide-binding protein 1 (GBP1) knockdown and overexpression, as determined by modified high-density survival assay. (a,b) GBP1 knockdown increased radiosensitivity both in clinically relevant radioresistant (CRR) and parental cells. GBP1 knockdown was carried out with Hs_GBP1_8. (c) Parental cells transfected with GBP1 (Parental GBP1) did not show significant changes in radioresistance compared to parental cells with an empty vector (Parental cont). Exponentially growing cells were seeded in 25-cm² flasks and incubated for 24 h; cells were then irradiated and incubated for another 72 h. Subsequently, 10% of the cells in each flask were seeded into another flask and incubated for a further 72 h and live cells were counted. scr, scramble siRNA.
was stronger than with GBP1_9, further experiments were carried out using GBP1_8.

Association of GBP1 overexpression and radioresistance. To determine whether GBP1 directly participates in the establishment of the radioresistant phenotype, we transfected parental cells with a GBP1 expression vector. We confirmed GBP1 protein overexpression in all transfected parental cells (Fig. S2c). The expression level was even higher in transfected cells of SAS and KB compared to their CRR cells. In all the parental cells, GBP1 transfection did not show significant change in radioresistance (Fig. 2c).

Relationship between suppressing GBP1 expression and radioresistance. Since GBP1 knockdown increased radiosensitivity, we examined the association of GBP1 expression and radiation-induced cell death by FACS. The frequency of apoptosis induced by 10-Gy X-rays was significantly higher in CRR cells with siGBP1 than with scrambled RNA in all cell lines examined (Fig. 3a). DNA double-strand breaks (DSBs) induced by 2-Gy X-rays were determined by γH2AX staining. GBP1 knockdown increased DNA DSBs by irradiation (Figs 3b,c and S3a,b).

Relationship between suppressing GBP1 and CSCs. We isolated surviving CSCs by exposure to long-term 0.5-Gy FR for 82 days from HepG2 cells. Microarray analysis showed that the mRNA level of GBP1 was significantly higher in HepG2 CSCs than in HepG2 cells (Fig. 4a). Additionally, the protein level of GBP1 was higher in HepG2 cells after FR than in non-irradiated HepG2 cells (Fig. 4b). Therefore, we examined the relationship between Oct4 expression and long-term FR. The frequency of Oct4-positive cells was higher in cells exposed to 0.5-Gy FR every 12 h for 30 days than in parental cells and was the highest in CRR cells (Fig. 4c). We examined whether Oct4-positive CSCs coincided with GBP1-positive cells by immunostaining. Even in CRRs, Oct4-positive cells

Original Article
GBP1-contributes to cancer cell radioresistance www.wileyonlinelibrary.com/journal/cas

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
constituted less than 8% of total cells (Fig. 4d). In contrast, GBP1 was positive in all CRR cells.

 GBP1 immunohistochemistry in xenotransplanted tumor tissues. SAS-R1 tumors transplanted into nude mice are also resistant to FR. (16) We found overexpression of both the GBP1 protein and mRNA in SAS-R1 tumors and KB-R tumors, compared with their parental cell-derived tumors (Fig. 5a). In order to determine the association of GBP1 with tumor radioresistance, we suppressed GBP1 by AteLoGene-delivered siRNA into animal tissues (Fig. S4) and irradiated with FR of 2-Gy/day for 5 days (Fig. 5b). GBP1 suppression alone did not affect the growth or microvessel density (MVD) of SAS and SAS-R1 tumors. However, SAS-R1 tumors shrank if combined with irradiation. In parental tumors, irradiation diminished the growth irrespective of GBP1 suppression.

 GBP1 immunohistochemistry of clinical samples. Immunohistochemical study of GBP1 was possible in 45 cases of HNC before treatment. Clinicopathological features of cases are shown in Table 1. We defined a case GBP1-positive if the nucleus and cytoplasm of more than 5% of tumor cells were positive for GBP1 (Fig. 5c). Only one GBP1-positive case and seven GBP1-negative cases out of a total of 45 cases were without recurrence or metastasis 5 years after chemoradiation.

Fig. 5. Distribution of guanine nucleotide-binding protein 1 (GBP1) in tumor tissues. (a) Compared with parental tumors, overexpression of the GBP1 gene and GBP1 protein was observed in clinically relevant radioresistant (CRR) tumor cells xenotransplanted into nude mice. (b) SAS-R1 tumors shrank due to fractionated radiation in combination with GBP1 suppression. SAS-R1 cells ($1 \times 10^7$) were injected into the right flank and SAS cells into the left flank of a mouse. (c) Representative positive staining of GBP1 in clinical cancer tissues. IHC, immunohistochemistry; IR, fractionated radiation with 2-Gy X-rays every 24h; ISH, in situ hybridization; scr, scramble siRNA; arrows, GBP1 positive cells.
### (a) Association of GBP1 expression and chemoradiotherapy resistance

| GBP1 | Recurrence or metastasis | Total |
|------|--------------------------|-------|
| +    | 20 1                      | 21    |
| -    | 17 7                      | 24    |

GBP1 positive cases were significantly more resistant to chemoradiotherapy than GBP1 negative cases (Behrens-Fisher test, \( P < 0.05 \)). Relative risk, 1.345; 95% confidence limit, 1.022 – 1.768.

### (b) Clinicopathological features of 45 cases of head and neck cancer

| Sample no. | Region          | Age, years | Gender | Differentiation | TNM classification | Stage   | Treatment                      | Total dose of irradiation (Gy) | Curative effect |
|------------|-----------------|------------|--------|-----------------|--------------------|---------|--------------------------------|---------------------------------|-----------------|
| 1          | Tongue          | 53         | Male   | Well            | T4N2bM0            | IV      | Chemoradiation→operation       | 40                              | Recurrent       |
| 2          | Tongue          | 54         | Female | Well            | T2N0M0             | II      | Chemoradiation→operation       | 40                              | Recurrent       |
| 3          | Larynx          | 57         | Male   | Moderate        | T2N0M0             | II      | Radiation                      | 70                              | Lymph node metastasis |
| 4          | Larynx          | 59         | Female | Moderate        | T2N0M0             | II      | Chemoradiation                 | 70                              | Recurrent       |
| 5          | Buccal cavity   | 59         | Male   | Moderate        | T1N2 cM0           | IV      | Chemoradiation→operation       | 70                              | Recurrent       |
| 6          | Buccal cavity   | 60         | Male   | Well > poor     | T4N2bM1            | IV      | Chemoradiation→operation       | 40                              | Recurrent       |
| 7          | Paranasal sinus | 60         | Male   | Well > poor     | T3N0M0             | III     | Chemoradiation→operation       | 70                              | Recurrent       |
| 8          | Paranasal sinus | 60         | Male   | Moderate        | T3N0M0             | III     | Chemoradiation→operation       | 50                              | Recurrent       |
| 9          | Paranasal sinus | 60         | Female | Moderate        | T3N0M0             | III     | Chemoradiation→operation       | 50                              | Recurrent       |
| 10         | Paranasal sinus | 61         | Male   | Moderate        | T3N0M0             | III     | Chemoradiation→operation       | 50                              | Recurrent       |
| 11         | Larynx          | 67         | Male   | Moderate        | T2N0M0             | II      | Radiation                      | 72                              | Recurrent       |
| 12         | Paranasal sinus | 69         | Male   | Poor            | T3N0M0             | III     | Chemoradiation→operation       | 50                              | Recurrent       |
| 13         | Hypopharynx     | 69         | Male   | Well > moderate | T4N2 cM0           | IV      | Chemotherapy→operation→radiation | 63                              | Recurrent       |
| 14         | Hypopharynx     | 71         | Male   | Moderate        | T2N0M0             | II      | Chemoradiation→operation       | 70                              | Recurrent       |
| 15         | Paranasal sinus | 74         | Male   | Moderate        | T4N1M0             | IV      | Radiation→operation            | 50                              | Recurrent       |
| 16         | Paranasal sinus | 75         | Female | Well            | T4N2bM0            | IV      | Chemoradiation                 | 60                              | Recurrent       |
| 17         | Buccal cavity   | 76         | Male   | Well            | T2N0M0             | II      | Chemoradiation→operation       | 50                              | Recurrent       |
| 18         | Buccal cavity   | 79         | Female | Well            | T4N2 cM0           | IV      | Chemoradiation→operation       | 40                              | Recurrent       |
| 19         | Larynx          | 79         | Male   | Moderate > well | T1bN0M0            | I       | Radiation                      | 66                              | Recurrent       |
| 20         | Buccal cavity   | 80         | Female | Well            | T4N2bM0            | IV      | Chemoradiation→operation       | 60                              | Recurrent       |
| 21         | Larynx          | 81         | Male   | Well > moderate | T1aN0M0            | I       | Radiation                      | 66                              | Recurrent       |
| Sample no. | Region          | Age, years | Gender | Differentiation | TNM classification | Stage | Treatment                                      | Total dose of irradiation (Gy) | Curative effect                                      |
|------------|-----------------|------------|--------|-----------------|--------------------|-------|-----------------------------------------------|-------------------------------|----------------------------------------------------|
| GBP1(–)    | Paranasal sinus | 46         | Male   | Well            | T3N0M0             | III   | Chemoradiationmoradiatin                    | 50                            | Recurrent and lymph node metastasis                |
| 22         | Larynx          | 51         | Male   | Well            | T2N0M0             | I     | Radiation→operation                         | 66                            | Recurrent                                          |
| 23         | Oropharynx      | 54         | Male   | Poor            | T4N2 cM0           | IV    | Chemoradiation→operation                    | 77                            | Recurrent                                          |
| 24         | Paranasal sinus | 56         | Male   | Moderate > well | T3N0M0             | III   | Chemoradiationoradiation                    | 70                            | Recurrent                                          |
| 25         | Paranasal sinus | 57         | Male   | Moderate        | T3N0M0             | III   | Chemoradiation→operation                    | 50                            | Recurrent                                          |
| 26         | Paranasal sinus | 57         | Male   | Moderate > poor | T3N2bM0            | IV    | Chemoradiationmoradiatpo                    | 50                            | Recurrent and lymph node metastasis                |
| 27         | Oropharynx      | 57         | Male   | Moderate        | T2N3M0             | IV    | Chemoradiation→operation                    | 60                            | Recurrent                                          |
| 28         | Paranasal sinus | 60         | Male   | Poor            | T3N0M0             | III   | Chemoradiation→operation                    | 50                            | Pathologically no recurrent/CR over 5 years        |
| 29         | Larynx          | 61         | Male   | Moderate > well | T2N0M0             | II    | Chemoradiation                               | 70                            | Pathologically no recurrent/CR over 5 years        |
| 30         | Rhinopharynx    | 61         | Male   | Moderate        | T1N2bM0            | IIB   | Chemoradiation→operation                    | 70                            | Pathologically no recurrent/CR over 5 years        |
| 31         | Oropharynx      | 66         | Male   | Poor            | T3N3M0             | IV    | Chemoradiation→operation                    | 70                            | Pathologically no recurrent/CR over 5 years        |
| 32         | Buccal cavity   | 67         | Male   | Well            | T4N2 cM1           | IV    | Chemoradiation→operation                    | 40                            | Recurrent and lymph node metastasis                |
| 33         | Tongue          | 68         | Male   | Moderate        | T1N0M0             | I     | Radiation                                    | 70                            | Pathologically no recurrent/CR over 5 years        |
| 34         | Paranasal sinus | 69         | Male   | Moderate > well | T4N2bM0            | IV    | Chemoradiation→operation                    | 50                            | Pathologically no recurrent/CR over 5 years        |
| 35         | Paranasal sinus | 71         | Male   | Moderate > well | T3N0M0             | III   | Chemoradiation→operation                    | 50                            | Pathologically no recurrent/CR over 5 years        |
| 36         | Larynx          | 71         | Male   | Well            | T1N0M0             | I     | Radiation→operation                         | 66                            | Recurrent                                          |
| 37         | Paranasal sinus | 71         | Female | Well            | T4N0M0             | IV    | Chemoradiationinustionec                    | 50                            | Recurrent                                          |
| 38         | Paranasal sinus | 72         | Male   | Moderate        | T4N0M0             | IV    | Chemoradiation→operation                    | 50                            | Recurrent                                          |
| 39         | Buccal cavity   | 74         | Male   | Well            | T4N2bM0            | IV    | Chemoradiation→operation                    | 40                            | Recurrent                                          |
| 40         | Buccal cavity   | 75         | Female | Well            | T4N1M0             | IV    | Chemoradiation→operation                    | 48                            | Recurrent                                          |
| 41         | Paranasal sinus | 76         | Female | Moderate        | T3N0M0             | III   | Chemoradiation→operation                    | 60                            | Recurrent                                          |
| 42         | Paranasal sinus | 77         | Male   | Moderate        | T4N0M0             | IV    | Chemoradiation→operation                    | 50                            | Recurrent                                          |
| 43         | Tongue          | 80         | Male   | Well            | T2N0M0             | II    | Radiation                                    | 70                            | Recurrent                                          |
| 44         | Larynx          | 82         | Male   | Well            | T1N0M0             | I     | Radiation                                    | 66                            | Pathologically no recurrent/CR over 5 years        |

CR, complete remission; GBP1, guanine nucleotide-binding protein 1.
treatment (Table 1a). GBP1-positive cases were significantly more resistant to chemoradiotherapy than GBP1-negative cases ($P < 0.05$, Behrens–Fisher test).

Discussion

Radiotherapy with FR is one of the major modalities for cancer treatment. Although tumors receive a large total dose, they sometimes recur and demonstrate radioresistance. In this study, we looked for genes whose overexpression was responsible for the radioresistant phenotype of CRR cells. In microarray analyses, we found two such candidate genes in common with human and murine CRR cells. We finally picked up only one gene, GBP1, whose overexpression in CRR cells was confirmed by RT-PCR. The translational level of GBP1 was closely correlated to the transcriptional step (Fig. 1d). The expression levels of GBP1 protein were not different between parental cells with and without 2-Gy irradiation. All the CRR and NOIR cells examined showed GBP1 overexpression, compared with their corresponding parental cells. This indicates that GBP1 protein overexpression is associated with radioresistance and is mainly regulated at the transcriptional step.

Knockdown of GBP1 cancelled radioresistance to the level of parental cells in all the CRR cells including HepG2 and KB with naturally low GBP1 expression (Figs 2a,b and S1b,c). This radiosensitization by GBP1 gene knockdown was also observed in transplanted SAS-R1 tumors (Fig. 5b). However, parental cells with GBP1 transfection did not demonstrate significant changes of radioresistance even in SAS and KB cells with much more GBP1 protein than their corresponding CRR cells (Figs 2c and S2c). These results indicate that GBP1 is essential to cope with radiation, but is not enough to shift the cell into CRR. Only GBP1 knockdown in CRR cells did not enhance apoptosis but induced apoptosis through increased radiation-induced DNA DSBs in an additive manner (Figs 3 and S3a,b). Sublethal damage that is substantiated by FR is suggested to be restored by homologous recombination repair (HRR) of DSBs.\(^{(21)}\) Therefore, prolongation of γH2AX foci in CRR cells by GBP1 knockdown is suggested to represent the deficiency in HRR of radiation-induced DSBs.\(^{(22)}\) A member of GTPases, RECQ5/βE DNA helicase is activated by GTP binding.\(^{(23)}\) These suggest that GBP1 is involved in radioresistance through HRR of DSBs. However, the failure of enhancing radioresistance by GBP1 overexpression in parental cells indicated that HRR requires multiple molecules other than GBP1.

Overexpression of GBP1 activates class III β-tubulin and ultimately leads to paclitaxel resistance in ovarian cancer cells.\(^{(12,13)}\) Nevertheless, GBP1 protein expression was not significantly changed by treatment with cisplatin or 5-fluorouracil (Fig. S5). Extrapolating from these findings, GBP1 plays a role in radioresistance but not in chemoresistance.

The GBP1 gene is located at tight junctions of intestinal epithelial cells of inflammatory bowel disease and its knockdown enhances apoptosis.\(^{(24)}\) We previously reported that inhibition of the AKT/cyclin D1 pathway suppresses acquired radioresistance through increased apoptosis. We need to study the relationship between GBP1 and the AKT/cyclin D1 pathway.\(^{(25)}\) In this study, GBP1 knockdown enhanced radiation-induced early apoptosis in CRR cells through the delay of DSB repair. We also reported that hyperinduction of autophagy is involved in radiation-induced cell death later than 5 days after radiation.\(^{(19)}\) Combined induction of apoptosis and autophagy hyperinduction would be effective to conquer CRR cancers.

Recently, we reported that exposure to FR with 0.5-Gy X-rays every 12 h for 82 days enriched CSCs, owing to their radioresistance.\(^{(20)}\) Microarray analysis showed that GBP1 gene expression increased along with the accumulation of total dose (Fig. 4b). Immunofluorescence of GBP1 staining was stronger in all CRR cells than their corresponding parental cells but not all CRR cells were Oct4-positive (Fig. 4c). These results indicate that radiotherapy, in combination with targeting GBP1-positive cancer cells, is more efficient in impeding cancer than targeting CSCs.

The growth rate of transplanted murine mammary tumors transfected with GBP1 is slower accompanied with lower MVD compared with those without transfection.\(^{(26)}\) Overexpression of GBP1 in human endothelial cells decreases apoptosis but inhibits cell proliferation.\(^{(11)}\) Patients with colorectal cancers with GBP1-positive stromal cells showed better prognosis than those with GBP1-negative cases.\(^{(27)}\) In this study, CRR tumors revealed higher MVD compared to their parental cell tumors, suggesting that GBP1 of cancer cells is not involved in tumor vasculature. It is interesting to study the expression and role of GBP1 in normal cells, especially in endothelial cells after FR.

Reports of the association of GBP1 with chemotherapeutic taxanes are conflicting; GBP1 is a marker of paclitaxel-resistant cancer cells\(^{(12)}\) and a marker of docetaxel-sensitive cancer cells.\(^{(28)}\) In this study, GBP1-positive HNC was clinically resistant to radiotherapy but was not associated with resistance to cisplatin and 5-fluorouracil. These results suggest that GBP1 plays a role in radioresistance, but not in chemoresistance, and may be a useful marker for screening of specifically radioresistant tumors before treatment.

The precise mechanism of GTP hydrolyzing activity of GBP1 and its role in signal transduction remains unknown.\(^{(29,30)}\) Our study is the first to reveal another aspect of GBP1, namely radioresistance. Our results suggest that the suppression of GBP1 transcription may overcome tumor radioresistance and that GBP1 could be used for screening radioresistant malignant tumors.

Acknowledgments

This study was supported in part by a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology, a Grant-in-Aid for Cancer Research from the Japanese Ministry of Health, Labor and Welfare, and a grant from the Research Seeds Quest Program, Japan Science and Technology Agency.

Disclosure Statement

The authors have no conflict of interest.

References

1 Tannock I. The Basic Science of Oncology, 4th edn. New York, NY: McGraw-Hill, Medical Publications, 2005.

2 Kuwahara Y, Li L, Baba T et al. Clinically relevant radioresistant cells efficiently repair DNA double-strand breaks induced by X-rays. Cancer Sci 2009; 100: 747–52.
